Serious adverse events are “an expected component of any clinical trial, especially large trials,” Johnson & Johnson said, noting that company protocols require a study to be suspended to determine if the serious adverse event is related. to the drug being evaluated and whether it is possible to resume the trial.
The recruitment of volunteers for phase 3 of the clinical trials began at the end of September, aiming to involve 60,000 participants in more than 200 locations in the United States and other countries. Tests were also taking place in Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa. Johnson & Johnson was the tenth group in the world to conduct phase 3 clinical trials against Covid-19 and the fourth in the United States.